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Abstract
Background: Birch pollen-allergic subjects produce polyclonal cross-reactive IgE antibodies that mediate pollen-associated
food allergies. The major allergen Bet v 1 and its homologs in plant foods bind IgE in their native protein conformation.
Information on location, number and clinical relevance of IgE epitopes is limited. We addressed the use of an allergen-
related protein model to identify amino acids critical for IgE binding of PR-10 allergens.
Method: Norcoclaurine synthase (NCS) from meadow rue is structurally homologous to Bet v 1 but does not bind Bet v 1-
reactive IgE. NCS was used as the template for epitope grafting. NCS variants were tested with sera from 70 birch pollen
allergic subjects and with monoclonal antibody BV16 reported to compete with IgE binding to Bet v 1.
Results: We generated an NCS variant (D29NCSN57/I58E/D60N/V63P/D68K) harboring an IgE epitope of Bet v 1. Bet v 1-type
protein folding of the NCS variant was evaluated by 1H-15N-HSQC NMR spectroscopy. BV16 bound the NCS variant and 71%
(50/70 sera) of our study population showed significant IgE binding. We observed IgE and BV16 cross-reactivity to the
epitope presented by the NCS variant in a subgroup of Bet v 1-related allergens. Moreover BV16 blocked IgE binding to the
NCS variant. Antibody cross-reactivity depended on a defined orientation of amino acids within the Bet v 1-type
conformation.
Conclusion: Our system allows the evaluation of patient-specific epitope profiles and will facilitate both the identification of
clinically relevant epitopes as biomarkers and the monitoring of therapeutic outcomes to improve diagnosis, prognosis, and
therapy of allergies caused by PR-10 proteins.
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Introduction
Millions of patients with allergies to tree pollen are sensitized
(produce IgE antibodies) to the major allergen of birch (Betula
verrucosa) pollen, Bet v 1 [1]. Bet v 1-binding IgE cross-reacts with
Bet v 1-homologous proteins from plant foods, leading to allergy to
such foods in a majority of birch pollen-allergic subjects [2].
Despite all efforts so far, a complete IgE epitope profile of Bet v 1
or of a Bet v 1-related allergen is still lacking, although knowledge
of clinically relevant IgE binding determinants would benefit
diagnosis, therapy, and current understanding of the sometimes
puzzling clinical phenomena of pollen-related food allergies.
Structural information on IgE epitopes of Bet v 1 and Bet v 1-
like allergens in foods is limited. To date only IgE epitopes of
allergens Art v 1 (pollen), Phl p 2 (grass), and b-lactoglobulin (milk)
were determined from X-ray crystallography and NMR spectros-
copy of IgE-allergen complexes [3–5]. Conformational IgE
epitopes of allergens from the PR10-protein family, however, are
unknown. Allergen variants carrying substitutions of either
individual or multiple residues to either attenuate or induce IgE
antibody binding (epitope grafting) identified individual residues
crucial for IgE recognition by Bet v 1 [6–10] and Bet v 1-type
allergens from apple [11,12], cherry [13,14], and celeriac [15]. In
addition, monoclonal antibodies have been used to localize
potential IgE epitopes of Bet v 1 and related allergens [10,16–
19]. The only structural information on an epitope of Bet v 1 to
date was obtained from X-ray crystallography of a complex
between the monoclonal Bet v 1-specific mouse IgG BV16 and the
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major isoform of Bet v 1, Bet v 1 a [20]. Binding of BV16 to Bet v
1 reduces serum IgE interactions, indicating competition of IgE
and monoclonal IgG for an overlapping binding site of Bet v 1
[21,22].
IgE-allergen interactions are usually analyzed with polyclonal
serum IgE, making it difficult to differentiate individual IgE
interaction sites. Engineering of recombinant allergen variants
often changes the native protein conformation which is essential
for IgE interaction. Thus we suggest to use a non-IgE binding
protein with allergen-like conformation as a scaffold that can be
modulated on the individual amino acid level to stepwise induce
IgE recognition capabilities. For this purpose we recently cloned,
expressed, purified, and characterized the enzyme norcoclaurine
synthase (NCS) from the meadow rue Thalictrum flavum as a
recombinant protein variant D29NCS [23,24]. As Bet v 1, NCS is
a member of the pathogenesis-related protein family (PR-10)
sharing the typical Bet v 1 protein fold [25], but has no known
allergenic properties. NCS is thus an ideal protein model
candidate to study epitopes of PR-10 allergens.
Here we aimed at establishing a recombinant model protein
system to specifically analyze epitopes of PR-10 allergens. For this
purpose we used the truncated variant D29NCS. To study the
impact of individual amino acids in IgE binding within NCS we
generated variants of D29NCS, analyzed their IgE antibody
binding with sera of birch pollen allergic subjects and determined
the cross-reactivity of suspected IgE epitopes grafted onto NCS.
Methods
Patients
Sixty-nine patients with a convincing history of pollinosis to
early flowering tree pollen and specific IgE levels.0.35 kUA/L to
birch pollen measured by ImmunoCAP (Thermo Fisher Scientific,
Uppsala, Sweden) were included as serum donors. Patients were
recruited at the Allergy Unit, Department of Dermatology,
University Hospital Zu¨rich, Switzerland, at the Hospital Borkum
Riff, Borkum, Germany, and at the Paul-Ehrlich-Institut, Langen,
Germany. Study participants provided written informed consent.
Ethics approval by the local ethics committee ‘Kantonale
Ethikkomission Zu¨rich, Switzerland’ of the University Hospital
in Zu¨rich, Switzerland and the local ethics committee ‘Ethik-
Kommission, Fachbereich Medizin der Johann Wolfgang Goethe-
Universita¨t, Frankfurt am Main, Germany’ of the University
Hospital in Frankfurt included consent form and consent
procedure. Sera 52–69 were published elsewhere [26]. Serum 70
was purchased from DLab Diagnose GmbH, Hamburg, Ger-
many. Serum from one non-allergic subject was used as negative
control for the specific IgE measurements. The positive serum pool
(IgE.0.35 kUA/L against D29NCS_5x) comprised sera 11, 14,
20–23, 32, 42, 47, and 70. The negative serum pool (IgE,
0.35 kUA/L against D29NCS_5x) comprised sera 4, 12, 18, 29–
31, 33, 40, 43, and 46.
Determination of specific IgE
Specific IgE levels to recombinant proteins were determined by
ImmunoCAP in Phadia 100 and 250 instruments (Thermo Fisher
Scientific, Uppsala, Sweden) according to the manufacturer’s
instructions. In the case of Bet v 1, Api g 1.01 and Cor a 1.04,
commercial ImmunoCAP tests were used, whereas for Pru av 1,
Dau c 1.01, NCS and its variants, experimental ImmunoCAPs
were manufactured by coupling the recombinant allergens
individually to the solid phase, as described elsewhere [27,28].
Cloning, expression and purification of D29NCS, Bet v 1
variants, and Bet v 1-related allergens
Mutations leading to the amino acid exchanges/insertion in
D29NCSN57/I58E/D60N/V63P, D29NCSN57/I58E/D60N/V63P/D68K, and
Bet v 1N43A/E45S/N47A/K55A were sequentially introduced into
pET29b-D29NCS [23] and pET15b-Bet v 1, respectively, with the
QuickChange kit from Stratagene (Heidelberg, Germany). All
protein variants were expressed and purified via their His6-tag
as described [23] with minor changes. To yield higher amounts
of soluble protein, the synthesis of the protein variants was
induced by the addition of 1 mM IPTG at 25uC followed by
incubation overnight. A synthetic gene encoding soy allergen
Gly m 4 was cloned into pET15b and purified as described
above for Bet v 1. The following Bet v 1-related allergens were
expressed and purified as described: Pru av 1 (cherry) [29], Dau
c 1 (carrot) [26], and Cor a 1.04 (hazelnut) [30]. rApi g 1.01
(celeriac) was purchased from Biomay, Vienna, Austria.
Circular dichroism
Far UV circular dichroism (CD) spectra of the D29NCS
variants were acquired at 293 K using a Jasco J-810 spectropo-
larimeter (Japan Spectroscopic, Gross-Umstadt, Germany) at a
band width of 1 nm and a sensitivity of 100 mdeg in a 0.2 cm cell.
All proteins were analyzed at a concentration of 2.5 mM in 5 mM
sodium phosphate, pH 7.0. Each measurement comprised the
average of 10 repeated scans between 260 and 190 nm.
NMR spectroscopy
NMR samples were prepared by dissolving lyophilized 15N-
labeled protein in 20 mM sodium phosphate, pH 7.0, 1 mM
DTT, 0.04% sodium azide and 10% D2O.
1H-15N-HSQC spectra
were recorded on a Bruker Avance 700 MHz spectrometer at
298 K. NMR data were processed using in-house software and
were visualized with NMR view [31].
Modelling of NCS variants
Structure predictions of D29NCSN57/I58E/D60N/V63P,
D29NCSN57/I58E/D60N/V63P/D68K, and Bet v 1N43I/E45S/N47D/
K55A were performed by using the Phyre server [32]. The
calculated models were based on the structures of wild type NCS
[25] (pdb 2VNE) and Bet v 1a [33] (pdb 1BV1), respectively, with
a confidence of 100% and a sequence coverage of at least 85%.
Binding of monoclonal antibody BV16 to Bet v 1 and
related allergens
Nunc Maxisorp plates (Fisher Scientific, Schwerte, Germany)
were coated overnight at room temperature with 250 ng/100 ml
proteins (D29NCS_5x; D29NCS; Dau c 1; Pru av 1; Bet v 1; Gly
m 4; Cor a 1), with 50 ng/100 ml Api g 1, and with 25 ng/100 ml
Bet v 1 and Bet v 1_4x in phosphate-buffered saline (PBS). After
blocking with PBS containing 2% BSA a dilution series of the
murine monoclonal anti-Bet v 1 antibody BV16 [34] was added
for 1 h at room temperature in PBS containing 0.05% Tween 20
and 0.1% BSA. Allergen-specific IgG was detected with horse-
radish peroxidase-conjugated goat anti-mouse IgG antibody
(A3673, SigmaAldrich, Taufkirchen, Germany) diluted 1:3000 in
PBS containing 0.05% Tween 20 and 0.1% BSA as described for
the IgE ELISA below.
Inhibition IgE ELISA
For IgE-ELISA inhibition experiments, Nunc Maxisorp plates
(Fisher Scientific, Schwerte, Germany) were coated overnight at
room temperature with 300 ng/100 ml D29NCS_5x with 10 mM
Epitope Grafting onto Allergen-Type Model Protein
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potassium phosphate-buffered saline (PBS). After blocking with
PBS containing 2% BSA, plates were incubated with the human
serum pool (dilution 1:10) and increasing concentrations (3*1025–
3 mg/well) of recombinant inhibitors (Bet v 1, Bet v 1_4x, Dau c
1.01, Pru av 1, Gly m 4, Cor a 1.04, and Api g 1.01, respectively)
for 3 hrs at room temperature with PBS containing 0.05% Tween
20 and 0.1% BSA. Allergen-specific IgE was detected with
horseradish peroxidase-conjugated mouse anti-human IgE anti-
body (Clone B3102E8, Southern Biotech via Biozol, Eching,
Germany) diluted 1:1000 with PBS containing 0.05% Tween 20
and 0.1% BSA. The substrate for horseradish peroxidase was
3,39,5,59-tetramethylbenzidine (Roth, Karlsruhe, Germany) and
the reaction was stopped by addition of 25% H2SO4. The
absorbance was measured at 450 nm.
For the IgE-ELISA inhibition experiment with monoclonal
antibody, ascites fluid of Bet v 1-specific antibody BV16 [34]
(diluted: 1:1000; 1:10000, and 1:100000 in PBS containing 0.05%
Tween and 0.1% BSA) was pre-incubated with 9 ng/well Bet v 1
as inhibitor for 2 hrs at room temperature. As a negative control,
dilution buffer alone was preincubated with Bet v 1. After blocking
with PBS containing 2% BSA, rBet v 1 and serum pool IgE diluted
1:10 (final concentration) were incubated on the plate for 3 hrs at
room temperature. Human IgE was detected as described below.
Indirect ELISA for IgE binding to Bet v 1 variants
For IgE-ELISA experiments, Nunc Maxisorp plates (Nunc via
Fisher Scientific, Schwerte, Germany) were coated overnight at
room temperature with 25 ng/100 ml recombinant Bet v 1 and
Bet v 1_4x, respectively with phosphate-buffered saline (PBS).
Blocking and IgE detection was done as described for IgE ELISA
above.
SDS-PAGE and immunoblot analysis
SDS-PAGE was performed with 15% separating gels and 5%
stacking gels using a discontinuous buffer system [35]. For
immunoblot analysis, 0.5 mg/cm of recombinant protein
D29NCS_5x was transferred onto 0.2 mm nitrocellulose mem-
branes by semi-dry blotting at 0.8 mA/cm2 for 1 h [36]. After
blocking with Tris-buffered saline (TBS) containing 0.3% Tween
20 blots were cut into strips and incubated overnight at room
temperature with 5 ml of human serum pool with or without
increasing amounts of recombinant allergens as inhibitors
(D29NCS_5x and Bet v 1, respectively) with TBS containing
0.05% Tween 20 (TBST 0.05%) and 0.1% BSA (TBST 0.05%–
0.1% BSA). After incubation for 1 h with horseradish peroxidase
labelled mouse anti-human IgE antibody (Clone B3102E8,
Southern biotech via Biozol, Eching, Germany), diluted
1:100000 with TBST 0.05%–0.1% BSA, IgE-binding proteins
were visualized by chemiluminescence (LumiGLO Reserve diluted
1:3, KPL via Medac, Wedel, Germany).
Mediator release from humanized Rat Basophil
Leukaemia (RBL) cells
The mediator release assay followed an established protocol
[37]. Briefly, RBL cells expressing the a-chain of human FceRI
were sensitized overnight with the positive serum pool of human
sera (diluted 1:20). After washing, cells were stimulated with serial
dilutions of allergens. Degranulation was quantified by photomet-
ric measurement of b-hexosaminidase activity in the culture
supernatants and was expressed as percent of the total cellular b-
hexosaminidase content obtained by lysing the cells with Triton X-
100 (Sigma-Aldrich, Steinheim, Germany) after correction for
spontaneous release (sensitized cells without allergen).
MS analysis of recombinant protein variants
The identity of recombinant proteins was confirmed by liquid
chromatography mass spectrometry (LC-MS). Recombinant
proteins were excised from Coomassie stained SDS-PAGE gels
and analyzed as described elsewhere [38]. Differing from this,
peptides were eluted with 25 mM NH4HCO3; 10% aceto nitrile
(ACN) and the digestion was stopped by adding 5% formic acid.
The peptides were analyzed by using a nano-ultra performance
LC system coupled to a nano-ESI- MS (nano Acquity UPLC
nanoESI Synapt-MS, Waters, Milford, US) with a 5 mm symmetry
180 mm620 mm c18 pre-column and a 1.7 mm BEH 130
100 mm6100 mm c18 separation column. After 3 minutes of
trapping (99% water at 5 ml/minute), a 30 minutes gradient (3–
40% ACN at 500 nl/minute) was applied to separate peptides. MS
was operated in V mode, acquiring MSE data and applying
standard parameters. Data analysis was performed with protein
lynx global server version 2.4 (Waters), searching an in house
database consisting of the Uniprot database (as of May 2011,
restricted to reviewed entries of eukaryotic organisms) and the
amino acid sequences of the recombinant variants D29NCS,
D29NCS_4x and D29NCS_5x. The identification of a protein was
accepted at a false positive rate of less than 4%; peptide mass
accuracy was 9 parts per million (ppm) or better.
Miscellaneous
Amino acid sequence alignments were carried out with
ClustalO [39]. 3D protein models were analyzed and illustrated
using PyMol [40].
Results
D29NCS variants have Bet v 1-type tertiary structure
IgE antibody binding to PR-10 allergens depends on the
presence of a native protein fold of the allergen. The crystal
structure of recombinant norcoclaurine synthase (NCS, pdb
2VNE) revealed a conformation identical to that of Bet v 1, even
though the sequence identity of these proteins is only 25% [25].
We recently optimized purification of a properly folded N-
terminally truncated variant of NCS (D29NCS), which comprises
the complete structurally corresponding amino acid sequence of
Bet v 1 [23]. We generated two D29NCS variants harboring single
amino acids of a Bet v 1 epitope for IgG that competes with IgE
[20,22] (Figures 1 and 2A). In addition, Asp68 of NCS was
exchanged for Lysine, a corresponding amino acid of Bet v 1
involved in IgE binding [22,41] and located directly adjacent to
the epitope. Initially we tested whether the rD29NCS variants
have the typical Bet v 1 conformation using circular dichroism
(CD) and nuclear magnetic resonance (NMR) spectroscopy
(Figure 2B, 2C and Figure S1). Both the CD and 1H15N-HSQC
NMR spectra of D29NCSN57/I58E/D60N/V63P (D29NCS_4x) and
D29NCSN57/I58E/D60N/V63P/D68K (D29NCS_5x) indicated that
the amino acid substitutions in the NCS variants did not change
the proteins’ secondary or tertiary structures and confirmed that
the native protein conformation is maintained in the variants
(Figure 2D).
D29NCS variants selectively bind IgE from sera of birch
pollen allergic subjects
To assess potential cross-reactive IgE binding to rD29NCS
variants, 70 sera of birch pollen allergic subjects were analyzed for
IgE binding to a range of PR-10 proteins using ImmunoCAP tests
(Table 1). All sera had sIgE to Bet v 1 (from 0.69 to.100 kUA/L)
and a majority to the PR-10 food allergens Pru av 1.01 (cherry, ,
0.35 to 58.2 kUA/L), Cor a 1.04 (hazelnut, ,0.35 to.100 kUA/
Epitope Grafting onto Allergen-Type Model Protein
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Figure 1. Grafting of an epitope onto D29NCS. Left panel: 13 of the 16 amino acids comprising the Bet v 1 epitope (Bet v 1E42/N43/I44/E45/G46/N47/
G48/G49/P50/G51/T52/R70/D72/H76/I86/K97) of mouse monoclonal IgG antibody BV16 (yellow). Six amino acids of the epitope are labeled. Lys55 of Bet v 1
located adjacent to the epitope is highlighted (green). Middle panel: the corresponding 13 residues of the Bet v 1 epitope for BV16 and a lysine
corresponding to K55 of Bet v 1 have been grafted onto D29NCS to generate D29NCS_4x (D29NCS N57/I58E/D60N/V63P) (not shown) and D29NCS_5x
(D29NCS N57/I58E/D60N/V63P/D68K). Right panel: corresponding surface area of D29NCS. Protein models were based on the structures of NCS (pdb 2VNE)
and Bet v 1a (pdb 1BV1), and modelled with a confidence of 100% and a sequence coverage of at least 85%.
doi:10.1371/journal.pone.0111691.g001
Figure 2. D29NCS, D29NCS_4x, and D29NCS_5x structures are virtually identical to the Bet v 1 structure. (A) Structural sequence
alignment. b-strands (underlined), helices (italic), and amino acid identities (green) to Bet v 1 (pdb: 1BV1) are 23.8% (D29NCS), 26.8% (D29NCS_4x),
and 27.5% (D29NCS_5x), respectively. (B) Circular dichroism of D29NCS variants. (C) Overlay of three 1H-15N-HSQC spectra of D29NCS variants. Black
arrows, signals numbered and named according to D29NCS. Black: D29NCS, blue: D29NCS_4x, red: D29NCS_5x. The arrows highlight signals of
selected amino acids that are expected to differ between the three D29NCS variants. Labeling is according to D29NCS scheme. (D) Overlay of
secondary structure topologies of D29NCS (grey), D29NCS_4x (blue), D29NCS_5x (red), and Bet v 1 (yellow).
doi:10.1371/journal.pone.0111691.g002
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L), Dau c 1.01 (carrot, ,0.35 to 98.5 kUA/L), and Api g 1.01
(celeriac, ,0.35 to 43.1 kUA/L), respectively. In contrast, most of
the sera (66/70, 94%) tested negative (,0.35 kUA/L) to D29NCS,
whereas 25/70 (36%) showed significant IgE binding (0.35 to
3.34 kUA/L, p ,0.0001) to D29NCS_4x and 50/70 (71%) to
D29NCS_5x (0.35 to 17.4 kUA/L, p,0.0001). Thus, gradual
substitution of certain amino acids of the low-IgE binding protein
D29NCS with those of Bet v 1 at the corresponding positions
induced significant binding of serum IgE from subjects with birch
pollinosis.
D29NCS_5x presents an IgE epitope that cross-reacts
with a subset of Bet v 1-homologous allergens
Since the majority of the patients’ sera IgE bound D29NCS_5x,
we asked whether this interaction was due to a Bet v 1-specific IgE
epitope presented by the D29NCS variant. Therefore we used
serum with sIgE to both Bet v 1 and D29NCS_5x and tested its
IgE interaction with the D29NCS_5x variant in the presence of
Bet v 1 (Figure 3). As expected, no IgE interaction of the serum
pool with D29NCS was observed (Figure 3A). In contrast, IgE
binding to D29NCS_5x was inhibited by D29NCS_5x itself and
Bet v 1 in a dose-dependent manner, suggesting the presence of an
IgE epitope shared by the two proteins.
Next, we asked whether the IgE epitope presented by
D29NCS_5x is cross-reactive with PR-10 food allergens. Thus,
we performed competitive IgE binding experiments (ELISA) with
the PR-10 food allergens Cor a 1.04, Gly m 4, Dau c 1.01, Api g
1.01, and Pru av 1, respectively (Figure 3B). Bet v 1 as well as Cor
a 1.04 and Gly m 4 competed for serum IgE binding to
D29NCS_5x, whereas only very low inhibition of IgE binding to
D29NCS_5x was observed with Api g 1, Pru av 1, and Dau c 1,
respectively. We conclude that the IgE epitope offered by
D29NCS_5x is not ubiquitous but specific for a subgroup of PR-
10 allergens.
The IgE cross-reactive epitope of D29NCS_5x overlaps
with an IgG binding site
D29NCS harbors 47% and D29NCS_5x 76% of the structurally
resolved IgG epitope (total of 16 amino acids) of Bet v 1, as defined
earlier [20]. We therefore asked whether the IgE binding epitope
of D29NCS_5x overlaps with the binding site of BV16 on Bet v 1.
Thus, we tested serum IgE binding of immobilized D29NCS_5x in
the presence of both Bet v 1 and increasing amounts of BV16
(Figure 3C). In the absence of BV16, IgE binding to D29NCS_5x
was inhibited to 84% by Bet v 1. The observed Bet v 1-induced
inhibition of IgE-D29NCS_5x interaction could, however, been
abolished by the monoclonal antibody BV16 in a dose-dependent
manner. This result suggests a structural overlap between the
individual cross-reactive IgE epitope of D29NCS_5x and the Bet v
1-specific IgG epitope recognized by monoclonal antibody BV16.
Furthermore, when we tested BV16 binding only Bet v 1, Gly m 4,
Cor a 1.04, and D29NCS_5x interacted markedly with the
monoclonal antibody, whereas Dau c 1.01, Api g 1.01 1, Pru av 1,
and D29NCS did not (Figure 3D).
Subtle structural differences define the IgE cross-
reactivity pattern of Bet v 1-homologous allergens
The differential interaction of D29NCS_5x and Pr-10 allergens
as above with both serum IgE and the Bet v 1-specific mouse
monoclonal BV16 let us to hypothesize that D29NCS_5x displays
an epitope shared only with Bet v 1, Cor a 1.04, and Gly m 4, but
not with Dau c 1.01, Api g 1.01, and Pru av 1. Thus, we
structurally aligned the epitope grafted onto D29NCS_5x and the
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corresponding surface areas of cross-reactive and non-cross-
reactive Bet v 1-related proteins (Figure 4). Residue by residue
comparison of the epitope revealed that N43, E45, N47, and K55
of Bet v 1 are shared with D29NCS_5x, Gly m 4, and Cor a 1.04,
but not with Pru av 1, Api g 1.01, and Dau c 1.01, thus mirroring
the IgE/IgG inhibition results (cf. Figure 3) and suggesting that
they are critical determinants of IgE cross-reactivity and BV16
binding. To challenge this hypothesis we investigated the
substitutional variant Bet v 1_4x (Bet v 1N43I/E45S/N47D/K55A).
As for D29NCS_5x and D29NCS_4x, the amino acid substitutions
did not alter the protein conformation according to CD and
1H15N-HSQC NMR spectroscopy (Figure S2). Serum IgE binding
to Bet v 1_4x was virtually identical to that of wild type Bet v 1
(Figure 5A). However, inhibition of IgE binding to D29NCS_5x
was strongly reduced by Bet v 1_4x as compared to Bet v 1
(Figure 5B), and interaction of monoclonal BV16 with Bet v 1_4x
was virtually abolished (Figure 5C). The capacity of Bet v 1_4x to
induce mediator release in humanized rat basophil leukemia cells
via allergen mediated cross-linking of receptor bound human IgE
was only slightly reduced as compared to wild type Bet v 1,
suggesting the presence of further IgE epitopes compensating for
the loss of one IgE epitope in Bet v 1_4x (Figure 5D). As expected,
the D29NCS variants did not induce mediator release due to the
lack of a second IgE epitope needed for allergen-mediated IgE
cross-linking. Since Bet v 1_4x could not compete with
D29NCS_5x for binding to serum IgE, we conclude that we have
identified an epitope in a subset of PR-10 allergens that binds
cross-reactive IgE and IgG.
Discussion
To analyze epitopes of allergens it is common to genetically
engineer specific allergen variants and test their antibody binding
capacity in comparison to the respective wild type allergen. A
residual response, however, can be misleading if the epitope to be
analyzed is conformational and proper binding of the antibody is
dependent on the native fold of the allergen. In this case any
observed compromised antibody-allergen interaction may well be
due to an altered protein conformation of the allergen variant
rather than due to the exchange of amino acids crucial for direct
antibody binding. Furthermore, the analysis of epitopes in
allergens is often hampered by the fact that the polyclonal serum
antibody repertoire makes it technically challenging to measure
and assign the functionality of single epitopes in the background of
the overall multiple antibody binding to the allergen. As the
Figure 3. D29NCS_5x presents a cross-reactive Ig epitope. (A) Inhibition of IgE binding to D29NCS_5x. Binding of serum IgE to D29NCS (lane
3) and to D29NCS_5x (lane 4) in the presence of increasing amounts of inhibitors D29NCS_5x (lanes 5–8) or Bet v 1 (lanes 9–12). No serum (lane 1)
and negative serum pool (lane 2) served as control. (B) Dose-dependent inhibition of IgE binding to surface-coated D29NCS_5x in the presence of
increasing concentrations of PR-10 allergens in ELISA. (C) Inhibition of IgE binding to surface-coated D29NCS_5x in the presence of both Bet v 1 and
serial dilutions of Bet v 1-binding monoclonal mouse IgG antibody BV16 (–: no BV16; 1025 to 1023: dilutions of BV16) in ELISA. (D) Binding of mouse
monoclonal IgG antibody BV16 to surface-coated Bet v 1-related proteins. 250 ng of protein (50 ng of Api g 1) was coated and incubated with
dilution series of the monoclonal BV16 in ELISA.
doi:10.1371/journal.pone.0111691.g003
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majority of epitopes of inhalative allergens is thought to be
conformational and the IgE repertoire of allergic patients to a
specific allergen is polyclonal, we circumvented these issues by
employing a model protein that i) does not interact with patients’
IgE, ii) has a stable allergen-like protein fold, and iii) allows the
analysis of individual antibody binding by amino acid substitu-
tions.
Here we analyzed a non IgE-binding variant of the PR-10
enzyme D29NCS of the common meadow rue with Bet v 1-type
protein structure [25]. We showed that amino acid insertion/
substitution did not alter the Bet v 1-like protein fold of D29NCS,
although it induced significant binding of IgE from sera of birch
pollen allergic subjects. IgE that bound to the epitope presented by
the model protein D29NCS_5x, cross-reacted with a subgroup of
PR-10 allergens. As analyzed with a Bet v 1 variant with
exchanged residues that mediate antibody binding to the epitope,
the observed IgE cross-reaction depended on a subset of amino
acids not ubiquitously present in PR-10 allergens. The functional
IgE epitope identified in this study overlaps with the known
binding site of the Bet v 1-specific murine monoclonal antibody
BV16.
The native protein conformation of Bet v 1 and highly likely
other PR-10 allergens is critical for IgE interaction since i) neither
sequential IgE binding peptides of Bet v 1 nor IgE binding
truncated variants of Bet v 1 have been described so far [42] ii) a
folding variant of Bet v 1 with native primary structure, but
permanently altered secondary structure has very low IgE
reactivity [43]. iii) several Bet v 1 variants with amino acid
substitutions that induced an altered protein conformation showed
reduced binding of serum IgE [7,44]. Thus we thoroughly studied
the secondary and tertiary structure of our model protein by CD
and 1H15N-HSQC NMR spectroscopy. The CD spectra of the
D29NCS variants were virtually identical and typical for PR-10
proteins. Furthermore, the 1H15N-HSQC spectra of the D29NCS
variants were superimposable for the majority of resonances, and
the spectra are in agreement with the notion of only minor local
Figure 4. Structural alignment of the Bet v 1 epitope forBV16 and amino acids critical for Ig cross-reactivity in PR-10 allergens.
Upper panel: model structures of D29NCS_5x and PR-10 allergens showing IgE cross-reactivity with D29NCS_5x. The amino acids comprising the
BV16-binding epitope and lysine 55 of Bet v 1 and the corresponding residues of D29NCS_5x, Gly m 4, and Cor a 1 are listed. Residues of the epitope
and of position 55 of Bet v 1 that are critical for Ig cross-reaction are highlighted in green. Lower panel: model structures of D29NCS and allergens
that do not show IgE cross-reactivity with D29NCS_5x. The amino acids corresponding to the epitope in the cross-reactive proteins are listed and
highlighted in green.
doi:10.1371/journal.pone.0111691.g004
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differences caused by the amino acid substitutions (cf. Figure 2C),
but otherwise identical protein conformation of the D29NCS
variants. Hence, the D29NCS variants have the typical PR-10
protein structure and fulfill the essential requirement for molecular
epitope analysis.
When we tested the impact of specific amino acids on serum IgE
binding, we found that amino acid substitutions in D29NCS with
structurally corresponding residues of Bet v 1 induced a significant
increase in IgE interaction of the model protein to up to four CAP
classes (cf. Table 1). As the protein folds of the D29NCS variants
were essentially identical, we concluded that the observed
serological IgE interaction of the model protein was caused solely
by the residues substituted. This hypothesis was further confirmed
by the allergen variant Bet v 1N43I/E45S/N47D/K55A (Bet v 1_4x)
which showed only little competition for serum IgE binding to
D29NCS_5x and did not bind the Bet v 1-reactive murine
monoclonal antibody BV16. Interestingly, residue E45 of Bet v 1
has already been identified as being critical for both IgE and BV16
interaction [17,22]. Thus we confirmed the existence of a
functional overlapping Bet v 1 epitope for human IgE and murine
IgG, with the majority (71%) of our study population having
serum IgE against the epitope displayed by D29NCS_5x.
Since Bet v 1-specific IgE cross-reacts with PR-10 food allergens
[2], we analyzed whether the functional epitope presented by
D29NCS_5x is also relevant for IgE cross-reactivity. Binding of
patients’ IgE to D29NCS_5x could be inhibited by Bet v 1, Gly m
4, and Cor a 1.04, respectively, suggesting that D29NCS_5x
displays an epitope shared by these allergens. Interestingly, the
PR-10 allergens Pru av 1, Dau c 1.01, and Api g 1.01 did not
cross-react with the NCS variant. Since the observed IgE reactivity
of the PR-10 allergens we studied correlated well with their
binding to the monoclonal antibody BV16, we assumed subtle
structural differences within the epitope between the allergens. A
sequential/structural alignment of the BV16 epitope indeed
revealed that five amino acids are identical and oriented in a
similar fashion among the cross-reactive proteins, but not in the
non-cross-reactive proteins. To confirm our hypothesis, we
generated a corresponding Bet v 1 variant to address these
sequential differences and found that the protein variant behaved
like the non-cross-reactive Bet v 1-homologous allergens with
regard to binding IgG (BV16) and competing with serum IgE for
D29NCS_5x.
Whereas the structural epitope of an antigen usually spans a
molecular surface area of about 400–1000 A˚2 and comprises
Figure 5. Amino acids critical forIgE and IgG cross-reactivity in a subgroup of Bet v 1-related proteins. (A) Binding of serial dilutions of
pool serum IgE to surface-coated equimolar amounts of Bet v 1 and Bet v 1_4x (Bet v 1N43I/E45S/N47D/K55A) in ELISA. (B) Inhibition of IgE binding to
surface-coated D29NCS_5x in the presence of either Bet v 1 or Bet v 1_4x in ELISA. (C) Binding of serial dilutions of monoclonal BV16 to surface-
coated equimolar amounts of Bet v 1 and Bet v 1_4x in ELISA. (D) Mediator release induced by recombinant NCS and Bet v 1 variants. Humanized RBL
cells were sensitized with a pool of human birch-specific sera. Cross-linking of membrane-bound human IgE by IgE-protein interaction and
subsequent release of b-hexosaminidase was determined with serial dilutions of the proteins.
doi:10.1371/journal.pone.0111691.g005
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10–25 amino acids, only a small subset of these residues dominates
the energetics of the antibody-antigen interaction and thus
constitutes the functional (active) epitope [45,46]. Our model
system is ideal for the analysis of functional epitopes, since even
low-affinity and individual antibody binding might be detected
due to the lack of multiple antibody binding sites in our model
protein.
Some information on functional IgE epitopes of Bet v 1 and
other PR-10 allergens has emerged in recent years. These studies
analyzed the interaction of IgE with either native Bet v 1 isoforms
or recombinant allergen variants [8,9,12–16,22,47]. Even though
great care had been taken to ensure a Bet v 1-like conformation of
the studied protein variants, they were inevitably targeted by a
polyclonal IgE antibody response, making it difficult to define the
importance and architecture of any single epitope structure.
Moreover, bioinformatic approaches are emerging that use either
peptide:IgE interaction or structure-based comparison of allergen
surfaces to localize Ig epitopes [18,26,48–50]. We believe that our
approach to induce measurable antibody interaction of allergen-
like protein variants is ideal to identify individual residues critical
for antibody interaction. However, the truncated version of NCS
used in this study still carries N- and C-terminal extensions that
might locally interfere with epitope analysis. Thus our future
research aims to further optimize our model protein system and
adapt it to the average number of amino acids of PR-10 allergens.
No mediator release in humanized rat basophil leukemia cells
sensitized with sera of birch pollen allergic subjects has been
observed with the D29NCS variants, indicating that no additional
IgE epitope that would mediate IgE receptor cross-linking is
displayed in the variants (cf. Figure 5D). In contrast, Bet v 1_4x
induced full wild type-like mediator release indicating that the lack
of one particular epitope is easily compensated by polyclonal
serum IgE. Thus our allergen model system also allows the
investigation of the role of epitopes of different affinities to IgE
antibodies in the IgE-mediated activation of basophils and mast
cells, a crucial step of Type I allergic reactions.
In summary, we have established a protein model system which
enables the specific analysis of functional IgE and IgG epitopes
and their homologies among PR-10 allergens. Upon single amino
acid substitutions of the non-allergenic protein variant D29NCS,
individual epitopes are identified in a residue-specific manner by
detection of newly generated immunoglobulin interactions of the
model protein. Our system allows the evaluation of patient-specific
epitope profiles and will facilitate both the identification of
clinically relevant epitopes as biomarkers and the monitoring of
therapeutic outcomes to improve diagnosis, prognosis, and therapy
of allergies caused by PR-10 proteins.
Supporting Information
Figure S1 1H-15N-HSQC spectra of different NCS vari-
ants. Spectra of (A) 400 mM D29NCS (black) (B) 250 mM
D29NCSN57/I58E/D60N/V63P (D29NCS_4x) (blue), and (C) 400 mM
D29NCSN57/I58E/D60N/V63P/D68K (D29NCS_5x) (red). The pro-
teins were measured in 20 mM sodium phosphate, pH 7.0, 1 mM
DTT, 0.04% sodium azide and 10% D2O at a 700 MHz
spectrometer at 298 K. Due to its solubility limit D29NCSN57/
I58E/D60N/V63P (D29NCS_4x) was measured at a lower protein
concentration.
(TIF)
Figure S2 Folding and structural integrities of Bet v 1
and Bet v 1_4x variant. (A) Circular dichroism of Bet v 1 and
Bet v 1_4x. (B) 1H-15N-HSQC spectra of Bet v 1 variants. Overlay
of the spectra of 100 mM Bet v 1 (petrol) and 100 mM Bet v 1_4x
(purple). The proteins were measured in 20 mM sodium
phosphate, pH 7.0, 1 mM DTT, 0.04% sodium azide and 10%
D2O at a 700 MHz spectrometer at 298 K.
(TIF)
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